Stocks · News reference
The trial advanced from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-11 AccNo: 0001493152-26-037170 Size: 204 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarImunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same
Read original at benzingaGainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Read original at benzinga